Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GAM-2203
- Development stage
- Preclinical
- Lead developer
- Avidin
- Modality
- Small Molecules
01
Overview
GAM-2203 is a small molecule drug candidate currently in preclinical development by Avidin Biotech for neuroprotection. The compound is designed to protect neuronal cells from damage or death, potentially offering a therapeutic strategy for various neurodegenerative diseases. As part of Avidin's portfolio, which focuses on small molecule discovery for central nervous system disorders, GAM-2203 is undergoing preclinical evaluation to establish its efficacy and safety profile before advancing to clinical trials. While specific molecular targets have not been publicly disclosed, the drug represents a targeted approach to preventing neuronal degeneration.
Beyond the preview
Go deeper on GAM-2203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GAM-2203.